LOL, WCVC and this crapper. Had ADTM but sold some time ago when it still existed. Stwits is way more active than Ihub. I still like the Ihub platform for creating different watchlists though.

Probably gambling and ass pounding shareholders. Sorry I don’t know. LOL

LOLOL. You are such a fraud. How do you even sleep at night?

Absolutely sell. Buy back in a week after the drop, but then again they will probably start diluting again, so maybe not.

Go away. If it closes at .18, post split would be $18. It will probably open at $12, then drop below $10. Easy money if shorting.

It was 24 million a few short months ago. Dump a thon.

Schwab doesn’t have level 2. Or I just haven’t found it.

We’re talking about AABB, not the Biden crime family.

If they max out the a/s of 3.6 billion @ $8.88 a share, that makes AABB a 32 billion dollar company. Larger than Barrick gold (GOLD), the largest gold company in the wold. LOLOLOLOL. You are so full of shit you need to be locked up.

As we hit a 52 week low of .0182. Your $8.88 a share that I’ve seen you claim puts the value of AABB at nearly 22 billion. Your price target is s complete joke and going beyond what even a ridiculous pumper would say.

7 analyst ratings still 100% buy. PT $4-$10.

This is not a 3 billion dollar company. Any kind of buyout I would expect .15-.20.

Could have just answered the question F;&&@face. Most of what I was reading just made it sound like it’s coming out of thin air until I found it.

The pro forma enterprise value of the combined company is up to $94 million, which includes up to $54 of cash held in the trust account of Redwoods, which is subject to redemption by Redwoods stockholders

So RWOD is going to basically clear out the trust fund to merge? Since their last filing shows 56.9 min in the trust.

Where does the 54 million in cash proceeds come from?

That’s gonna sting. Double zeros for sure.

Everything I see shows pullback is not over. Might be a pump out dumpity.

$3.4 million in inside buys between 6-20 and 6-27. Price target $5. 7 analyst ratings 100% buy

Peeps don’t trust the otc that’s why. Back of my mind says what kind of swindler is going to swoop in and say, whoops!! Language in the contract was wrong, peeon common shareholders get nothing.

That’s why it doesn’t move. IMO

They can’t tell us all this. They are not smart enough to know what equipment they have or how much it costs. Well they would if they actually had it. Don’t get started on how much AABBG has been sold or at what price or how many NFTs. That would require math, and have it make sense. I don’t think they can make numbers up and make sense. Unless they have real numbers, which they probably don’t. AIMO

3 days of dips. Time sink or swim tomorrow.

Second highest volume day in recent history. Look for dip and rip tomorrow.

Maybe TD Is implementing Schwab rules for the transition happening in May?

Valid point. Look at PLPL, 2 failed mergers so far. Going on the third now and stock price goes nowhere due to no confidence that it will go through. Could have sold the highs but didn’t. Now I sit and wait again. So yes individual strategy.

NEW 2 YEAR LOW EVERY MONTH!!! TO THE MOON THEY SAY!!! IF I TYPE IN ALL CAPS IT MUST BE TRUE!!! AABB IS GOLDEN REMEMBER?!?! WHAT A JOKE THIS SCAM HAS BECOME!!! IMO!!!

!!!! MORE EXCLAMATION POINTS !!!!

That’s what I’m counting on when I bought yesterday

Going on 6 months now since the supposed r/s. What are the chances it was denied? You know with warrants being excluded from r/s. Red flag money grab by Bigger. Reverse split, cash in those warrants, cha-ching, do nothing, make lots of money, hang the shareholders out to dry.

Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM) today announced encouraging initial data from its ongoing Phase 1 trial (APEX-01 (NCT04662580)) investigating ARX517, Ambrx's proprietary anti-PSMA ADC, in prostate cancer patients. APEX-01 is a Phase 1, first-in-human, open label dose escalation and dose expansion trial enrolling patients with advanced prostate cancer whose tumors have progressed on at least two prior FDA-approved treatments. APEX-01 is the only ongoing clinical trial in the United States targeting PSMA with an ADC. APEX-01 opened for enrollment July 2021 and this is the first data being reported in the study.

In the Phase 1 dose-escalation portion of the study, ascending dose levels of ARX517 is administered as a single agent every 3 weeks. The primary endpoints are safety, tolerability and pharmacokinetics. The key secondary endpoint is objective decline of prostate-specific antigen (PSA) from baseline and/or tumor shrinkage. PSA is a protein produced by the prostate gland and is commonly used as a biomarker to diagnose and follow prostate cancer. A greater-than or equal to 50% reduction in PSA levels from baseline is considered clinically relevant and has been shown to correlate with improved overall survival in prostate cancer.

To date, 22 prostate cancer patients have been dosed across 7 dose level Cohorts starting from 0.32 mg/kg to 2.4 mg/kg. A minimum of 3 patients were enrolled at each Cohort. The dose limiting toxicity (DLT) period is 21 days.

Of 22 patients evaluable for safety, no drug-related severe adverse events (SAEs) or grade greater-than or equal to3 treatment-related AEs have been observed. ARX517 was well-tolerated with grade 1 or 2 treatment-related adverse events being reported. The maximum tolerated dose (MTD) has not yet been reached.PSA reductions of > 30% have been observed in Cohorts 2-5, beginning at the second to lowest dose, 0.64 mg/kg.In Cohort 6 (2.0 mg/kg dose), 3 of 3 (100%) patients experienced a greater than 50% reduction in PSA levels. 2 of 3 patients experienced a greater than 90% reduction of PSA levels. One of three patients had soft tissue measurable disease and experienced a RECIST v1.1 partial response at the first on-treatment scan.Three patients have been dosed in Cohort 7 with no DLTs.

"The preliminary data from patients with prostate cancer are highly encouraging," said Dr. Michael Schweizer, MD, an Investigator on APEX-01 and Associate Professor

Division of Medical Oncology, Fred Hutchinson Cancer Research Center. "Seeing a greater than 50% reduction in PSA levels in three of three patients at the 2.0 mg/kg dose level in this patient population is impressive, and ARX517 appears to be well tolerated so far. I am very optimistic for its future development. We look forward to more data from APEX-01, as the dose escalation continues in this difficult-to-treat patient population."

The Safety Monitoring Committee (SMC) meeting to discuss the next dose Cohort is scheduled for the end of February 2023. Not all patients have undergone or completed tumor assessments and the data are not yet final.

Ambrx plans to report further information regarding ARX517 and the APEX-01 study at its upcoming Analyst and Investor Day scheduled for February 24, 2023. Additional data are planned for presentation at an upcoming medical meeting.

The stupidity of some. They see news with words like investigation and delisting and panic sell or short the stock. Read it for F&@ks sake.

That would be nice to break even since I’ve been a bag holder from the last reverse split. Average cost for me is $9.74.

Shares getting locked up. RSV vaccine in the pipeline. Could it get FDA fast track?

What exactly makes this a 1 billion dollar company?

The problem with doing the r/s now is it looks like a pump and dump dilution scam. Which it may be. Doing the r/s now the share price is going to get slammed to the point another r/s is in the near future to try to uplist again. instead of getting everything in order, name change, ticker change and letting the stock price grow organically to copper range, then do the r/s. He’s an idiot and has already doomed the plan of this company. If his plan is self enrichment dilution scam, he’s right on track.

When support is lower every week, is it holding like a rock?! LMFAO

Love how the company continues to let the share price make lower lows and lower highs. It’s very transparent that this stock is a POS. Nothing will happen unless they have audited financials to prove exactly what they have, nothing…. Otherwise they would have done it already. IMO.

Price action and trading pattern the last 2 weeks it wouldn’t shock me if the r/s gets canceled. It should be tanking right now.

Why is bigger buying when a RS is coming?

It’s like a tall tale of mm trading. 911 means pending news or pr is on the way. I have yet to see any connection on any 911 trade ever that coincide with a new out or pr other than coincidence.

https://otc.financial/list-of-market-maker-signals/

One 911 buy today. Now that’s comical.

They are in the process of growing their bank accounts not a business. 100% gold backed token? Then they should prove they actually own gold. But they won’t since they don’t own any gold imo.

While the short report has value, it has nothing to do with naked shorts. The report you are showing is intraday shorts that may indeed reveal if shares are becoming difficult for mms to obtain through the daily process of buys and sells. Without out it the mms would literally have to wait for a buyer to buy someone’s sell, and the other way around. Look up any ticker history and one day it may be 30% and the next day 80%.